# Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies

> **NCT04475523** · PHASE1 · COMPLETED · sponsor: **Curis, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** CI-8993

## Key facts

- **NCT ID:** NCT04475523
- **Lead sponsor:** Curis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-22
- **Primary completion:** 2023-05-19
- **Final completion:** 2023-05-19
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04475523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04475523, "Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04475523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*